ArticleToxicology reports2019
Comparison of monoamine oxidase inhibition by cigarettes and modified risk tobacco products.
Article in Toxicology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- What is the Addictive Potential from Vaping?Nordisk alkohol- & narkotikatidskrift : NAT · 2026Article
- Targeting monoamine oxidases for the treatment of betel quid dependence: a potential pharmacological and neurobiological approach.Frontiers in pharmacology · 2026Review
- Cardiac Autonomic Dysfunction and Increased Oxidative Stress in Conventional Cigarettes and E-Cigarettes: Heart Rate Variability as a Cardiovascular Predictor.Antioxidants (Basel, Switzerland) · 2025Review
- Monoamine Oxidase Inhibitors Present in Tobacco Modulate Dopamine Balance Via the Dopamine Transporter.ACS chemical neuroscience · 2025Article
- Reinforcement and MAO-A inhibition in heated tobacco products: flavor and brand variations.Frontiers in psychiatry · 2025Article
- A scoping review of the toxicity and health impact of IQOS.Tobacco induced diseases · 2024Article
- MAOA uVNTR Polymorphism Influence on Older Adults Diagnosed with Diabetes Mellitus/Systemic Arterial Hypertension.Journal of aging research · 2023Article
- Commentary: Harmane potentiates nicotine reinforcement through MAO-A inhibition at the dose related to cigarette smoking.Frontiers in molecular neuroscience · 2023Article
- Monoamine oxidase inhibition in cigarette smokers: From preclinical studies to tobacco product regulation.Frontiers in neuroscience · 2022Review
- Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca.Frontiers in pharmacology · 2022Review
- Cigarette Smoke Extract, but Not Electronic Cigarette Aerosol Extract, Inhibits Monoamine OxidaseFrontiers in neuroscience · 2022Article
- Harmane Potentiates Nicotine Reinforcement Through MAO-A Inhibition at the Dose Related to Cigarette Smoking.Frontiers in molecular neuroscience · 2022Article
- Non-nicotine constituents in cigarette smoke extract enhance nicotine addiction through monoamine oxidase A inhibition.Frontiers in neuroscience · 2022Article
- Effects of Natural Monoamine Oxidase Inhibitors on Anxiety-Like Behavior in Zebrafish.Frontiers in pharmacology · 2021Article
- Nicotine pharmacokinetics of electronic cigarettes: A pooled data analysis from the literature.Toxicology reports · 2021Article
- Smokeless tobacco induced biophysical and biochemical alterations in the plasma, erythrocytes, and platelets of panmasala users: Subsequent biological effects.Toxicology reports · 2020Article
- Comparative and cumulative quantitative risk assessments on a novel heated tobacco product versus the 3R4F reference cigarette.Toxicology reports · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adverse effects of cigarette smoking are well documented, and the two main strategies for reducing smoking prevalence are prevention of smoking initiation and promotion of smoking cessation. More recently, a third and complementary avenue, tobacco harm reduction has emerged, which is aimed to reduce the burden of smoking-related diseases. This has been enabled by the development of novel products such as electronic cigarettes (e-cigarettes) and heated tobacco products, designed to deliver nicotine with significantly reduced levels of the toxicants that are emitted by cigarettes. Several potential modified risk tobacco products (pMRTP) have been reported to emit significantly less toxicants than cigarettes and significantly reduce toxicant exposure in smokers who switch completely to such products. These are two prerequisites for pMRTPs to reduce harm and the risk of smoking-related disease. However, concerns remain regarding the addictive nature of these products. Smoking addiction is a complex phenomenon involving multiple pharmacological and non-pharmacological factors. Although the main pharmacological substance associated with smoking addiction is nicotine, accumulating evidence suggests that nicotine mostly acts as a primary reinforcer and that other factors are involved in establishing smoking addiction. Inhibition of monoamine oxidases (MAO)-mammalian flavoenzymes with a central role in neurotransmitter metabolism-has also been suggested to be involved in this process. Therefore, we aimed to comparatively investigate the ability of several types of pMRTPs and cigarette smoke (3R4F) to inhibit MAO activity. The results showed that the heated tobacco product Tobacco Heating System (THS) 2.2 and the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.